Shares of Juniper Networks, Inc. (NYSE:JNPR) ended Wednesday session in red amid volatile trading. The shares closed down -0.46 points or -1.92% at $23.48 with 23.40 million shares getting traded. Post opening the session at $23.40, the shares hit an intraday low of $23.27 and an intraday high of $23.63 and the price vacillated in this range throughout the day. The company has a market cap of $8.76 billion and the numbers of outstanding shares have been calculated to be 382.96 million shares.
Juniper Networks, Inc. (JNPR) announced security portfolio enhancements that extend threat prevention deeper into the network – down to the switch level. These new and upgraded solutions, launched at Juniper’s NXTWORK 2016 user conference, include a new Policy Enforcer, which automates the enforcement of security policies across the network and quarantines infected endpoints to prevent threats across firewalls and switches through Junos® Space Security Director. Additionally, Juniper Networks® Sky Advanced Threat Prevention (ATP) is now available on the vSRX Virtual Firewall as well as across the SRX Series Services Gateways, extending protection from sophisticated malware across virtual and physical firewalls. Juniper has also given customers the flexibility to meet their specific needs through new mid-range SRX4000 Series firewalls, optimized for hybrid cloud and enterprise campus environments.
Shares of International Business Machines Corp. (NYSE:IBM) ended Wednesday session in red amid volatile trading. The shares closed down -0.50 points or -0.32% at $154.29 with 2.96 million shares getting traded. Post opening the session at $154.97, the shares hit an intraday low of $153.08 and an intraday high of $154.97 and the price vacillated in this range throughout the day. The company has a market cap of $145.38 billion and the numbers of outstanding shares have been calculated to be 955.84 million shares.
International Business Machines Corp. (IBM) announced that many IBM U.S. employees fighting cancer will be able to tap into Watson for insights into their cancer treatment as well as potential clinical trial options. Through a unique collaboration with Best Doctors, an expert clinical consultation provider, qualifying IBMers and their family members will have access to Watson’s suite of oncology offerings for insights on cancer treatment options, when covered under IBM’s U.S. medical plan. The benefit will be available as of January 1, 2017.
With the patient’s permission, the Best Doctors team will collect medical records and feed relevant data into Watson. Watson will then generate a report, which will be reviewed by world-renowned expert oncologists in the Best Doctors network. The final assessment will be provided to the patient and their treating oncologist.
“For anyone receiving the diagnosis, or supporting a loved one through it, cancer can be overwhelming,” said Kyu Rhee, MD, chief health officer, IBM Watson Health. “Now a second opinion staffed by the powerful combination of Watson and world-renowned oncologists in the Best Doctors network is readily available. With this first-ever U.S. rollout of the technology, the full breadth and depth of Watson’s services can benefit an entire population of individuals who need them.”